S&P 500   2,997.97 (+0.28%)
DOW   27,026.16 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
NFLX   293.50 (+2.52%)
DIS   132.86 (+1.53%)
S&P 500   2,997.97 (+0.28%)
DOW   27,026.16 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
NFLX   293.50 (+2.52%)
DIS   132.86 (+1.53%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Agios PharmaceuticalsAkcea TherapeuticsPortola PharmaceuticalsXencorCambrex
SymbolNASDAQ:AGIONASDAQ:AKCANASDAQ:PTLANASDAQ:XNCRNYSE:CBM
Price Information
Current Price$33.75$18.95$27.97$36.50$59.49
52 Week RangeBuyBuyBuyBuyHold
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$66.17$36.00$40.83$45.29$52.40
% Upside from Price Target96.05% upside89.97% upside45.99% upside24.07% upside-11.92% downside
Trade Information
Market Cap$1.98 billion$1.82 billion$1.88 billion$2.06 billion$2.01 billion
Beta2.311.52.091.372.19
Average Volume567,810448,978795,142345,562432,702
Sales & Book Value
Annual Revenue$94.39 million$64.87 million$40.13 million$40.60 million$532.09 million
Price / Sales21.0127.1847.6250.903.76
CashflowN/AN/AN/AN/A$3.89 per share
Price / CashN/AN/AN/AN/A15.29
Book Value$11.82 per share$3.10 per share$1.36 per share$9.28 per share$19.48 per share
Price / Book2.866.1120.573.933.05
Profitability
Net Income$-346,020,000.00$-225,820,000.00$-350,220,000.00$-70,410,000.00$92.41 million
EPS($6.03)($2.74)($5.01)($1.31)$2.77
Trailing P/E RatioN/AN/AN/AN/A21.50
Forward P/E RatioN/AN/AN/AN/A42.49
P/E GrowthN/AN/AN/AN/A$4.67
Net Margins-383.05%-65.62%-379.94%28.46%9.41%
Return on Equity (ROE)-59.89%-43.87%-352.12%8.40%8.20%
Return on Assets (ROA)-45.90%-35.25%-67.90%7.50%3.97%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.21%0.04%453.47%0.02%0.78%
Current Ratio5.96%6.48%3.63%8.27%2.44%
Quick Ratio5.91%6.32%3.61%8.27%1.77%
Ownership Information
Institutional Ownership PercentageN/A25.39%N/A84.06%N/A
Insider Ownership Percentage3.16%4.10%4.50%4.33%1.41%
Miscellaneous
Employees4822483241561,732
Shares Outstanding58.75 million93.03 million68.32 million56.62 million33.66 million
Next Earnings Date11/7/2019 (Estimated)11/4/2019 (Estimated)11/5/2019 (Confirmed)11/4/2019 (Estimated)11/14/2019 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
 Agios PharmaceuticalsAkcea TherapeuticsPortola PharmaceuticalsXencorCambrex

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel